ERBB2 and gastric cancer: T-DXd has been evaluated as treatment of several HER2-expressing cancers, including HER2-positive and HER2-low breast cancer, HER2-positive gastric cancer, HER2-expressing colorectal cancer, and HER2-expressing or -mutated NSCLC [9].